Atreca, Inc. announced that Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles, presented safety and efficacy data from the ongoing Phase 1b study of ATRC-101 in patients with select advanced solid tumors cancer during an oral abstract session on Sunday, June 4 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. The presentation provided a summary of clinical data collected as of a February 17, 2023, data cut-off date. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0941 USD | -0.95% | +0.32% | -28.71% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.71% | 3.77M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- BCEL Stock
- News Atreca, Inc.
- Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract